MA47541A - Procédé permettant de produire des progéniteurs de lymphocytes t - Google Patents

Procédé permettant de produire des progéniteurs de lymphocytes t

Info

Publication number
MA47541A
MA47541A MA047541A MA47541A MA47541A MA 47541 A MA47541 A MA 47541A MA 047541 A MA047541 A MA 047541A MA 47541 A MA47541 A MA 47541A MA 47541 A MA47541 A MA 47541A
Authority
MA
Morocco
Prior art keywords
producing
lymphocyte progenitors
progenitors
lymphocyte
Prior art date
Application number
MA047541A
Other languages
English (en)
Inventor
Isabelle Andre
Marina Cavazzana
Kuiying Ma
John Tchen
Original Assignee
Hopitaux Paris Assist Publique
Fondation Imagine Inst Des Maladies Genetiques
Inst Nat Sante Rech Med
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Fondation Imagine Inst Des Maladies Genetiques, Inst Nat Sante Rech Med, Univ Paris Descartes filed Critical Hopitaux Paris Assist Publique
Publication of MA47541A publication Critical patent/MA47541A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
MA047541A 2017-02-13 2018-02-12 Procédé permettant de produire des progéniteurs de lymphocytes t MA47541A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13

Publications (1)

Publication Number Publication Date
MA47541A true MA47541A (fr) 2019-12-18

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047541A MA47541A (fr) 2017-02-13 2018-02-12 Procédé permettant de produire des progéniteurs de lymphocytes t

Country Status (17)

Country Link
US (5) US20200046767A1 (fr)
EP (2) EP3580330B1 (fr)
JP (2) JP7164798B2 (fr)
KR (1) KR102666158B1 (fr)
CN (1) CN110506110B (fr)
AU (1) AU2018217404B2 (fr)
BR (1) BR112019016672A8 (fr)
CA (1) CA3053294A1 (fr)
DK (1) DK3580330T3 (fr)
ES (1) ES2931530T3 (fr)
HU (1) HUE060548T2 (fr)
IL (1) IL268641B2 (fr)
MA (1) MA47541A (fr)
PL (1) PL3580330T3 (fr)
PT (1) PT3580330T (fr)
WO (1) WO2018146297A1 (fr)
ZA (1) ZA201905470B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019016672A8 (pt) * 2017-02-13 2022-11-22 Hopitaux Paris Assist Publique Método para gerar progenitores de células t
US20200308540A1 (en) * 2017-09-29 2020-10-01 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
WO2019157597A1 (fr) 2018-02-14 2019-08-22 Sunnybrook Research Institute Procédé de génération de cellules de la lignée des lymphocytes t
WO2020051453A1 (fr) * 2018-09-07 2020-03-12 Wisconsin Alumni Research Foundation Génération de cellules progénitrices hématopoïétiques à partir de cellules souches pluripotentes humaines
AU2020265737A1 (en) * 2019-05-01 2021-12-02 Immunebridge Inc. Methods of making oligopotent and unipotent precursors
CN114828876A (zh) * 2019-06-24 2022-07-29 洛杉矶儿童医院 Bcl11b过表达以增强人胸腺生成和t细胞功能
JP2023502965A (ja) * 2019-11-14 2023-01-26 ウィリアム ザンドストラ，ピーター 前駆ｔ細胞を製造するための培地処方および方法
WO2021200901A1 (fr) * 2020-03-31 2021-10-07 国立大学法人京都大学 Procédé de production de progéniteurs des lymphocytes t
AU2021385606B2 (en) 2020-11-30 2026-02-05 Cho Pharma, Inc. Antibody for enrichment of cells
WO2022187704A1 (fr) * 2021-03-05 2022-09-09 Factor Bioscience Inc. Thérapies par cellules immunitaires modifiées
US20240240144A1 (en) * 2021-05-25 2024-07-18 Universiteit Gent Generating t cell precursors via agonizing tumor necrosis factor receptor 2
JP2024542151A (ja) * 2021-11-04 2024-11-13 エーピーエイチピー（アシスタンス パブリック－オピトークス ド パリ） Ｎｋ細胞の生成法
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
JP2026504155A (ja) 2023-01-27 2026-02-03 ノッチ セラピューティクス（カナダ）インコーポレイテッド 幹細胞／前駆細胞からｔ細胞系統集団を生成するための方法
CN121263194A (zh) * 2023-02-22 2026-01-02 梅里特斯细胞治疗公司 用于胸腺再生的方法
WO2025217462A1 (fr) 2024-04-10 2025-10-16 Garuda Therapeutics, Inc. Cellules immunocompatibles pour thérapies cellulaires allogéniques pour couvrir des populations mondiales, ethniques ou spécifiques à une maladie
WO2025219552A1 (fr) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Procédé de production de progéniteurs de lymphocytes t à partir de cellules souches pluripotentes humaines
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
AU753975B2 (en) 1997-12-04 2002-10-31 Duke University Methods of isolating and using CD7+CD34-Lin-hematopoietic cells
WO2009097140A1 (fr) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Procédés d'immunothérapie tumorale prête à l'emploi utilisant des précurseurs de lymphocytes t allogéniques
BRPI0919020B8 (pt) 2008-09-12 2021-05-25 Cryopraxis Criobiologia Ltda uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
WO2010051634A1 (fr) 2008-11-07 2010-05-14 Sunnybrook Health Sciences Centre Lymphocytes t progéniteurs humains
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
JP6165627B2 (ja) 2010-04-09 2017-07-19 フレッド ハッチンソン キャンサー リサーチ センター Ｈｌａの適合なしに造血機能を提供するための組成物および方法
WO2013074916A1 (fr) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Lymphocytes t car+ génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et/ou le système hla
US9834755B2 (en) * 2011-12-08 2017-12-05 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20150352180A1 (en) 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
WO2015017755A1 (fr) 2013-08-02 2015-02-05 The Regents Of The University Of California Modification d'une immunité antivirale médiée par les cellules t par des cellules souches et des récepteurs d'antigène chimériques
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
CN106459924A (zh) 2014-04-23 2017-02-22 得克萨斯州大学系统董事会 用于疗法中的嵌合抗原受体(car)及其制备方法
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
WO2016039933A1 (fr) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vecteur lentiviral pour le traitement de troubles de l'hémoglobine
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
AU2016278959A1 (en) * 2015-06-17 2018-01-18 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
WO2017173551A1 (fr) 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Procédé de production de cellules t progénitrices à partir de cellules souches et/ou progénitrices et son utilisation
BR112019016672A8 (pt) * 2017-02-13 2022-11-22 Hopitaux Paris Assist Publique Método para gerar progenitores de células t

Also Published As

Publication number Publication date
JP7164798B2 (ja) 2022-11-02
DK3580330T3 (da) 2022-12-05
PT3580330T (pt) 2022-12-06
IL268641B2 (en) 2024-10-01
US11426430B2 (en) 2022-08-30
ES2931530T3 (es) 2022-12-30
JP2022185024A (ja) 2022-12-13
CN110506110B (zh) 2024-09-06
AU2018217404A1 (en) 2019-09-05
US20210169934A1 (en) 2021-06-10
CN110506110A (zh) 2019-11-26
CA3053294A1 (fr) 2018-08-16
AU2018217404A2 (en) 2019-09-19
US20210169935A1 (en) 2021-06-10
US20200046767A1 (en) 2020-02-13
BR112019016672A2 (pt) 2020-04-14
US20230293586A1 (en) 2023-09-21
BR112019016672A8 (pt) 2022-11-22
RU2019125600A (ru) 2021-03-15
US11638723B2 (en) 2023-05-02
EP3580330B1 (fr) 2022-08-31
IL268641B1 (en) 2024-06-01
EP3580330A1 (fr) 2019-12-18
US20200390817A1 (en) 2020-12-17
AU2018217404B2 (en) 2024-03-28
JP2020513844A (ja) 2020-05-21
KR20190117550A (ko) 2019-10-16
PL3580330T3 (pl) 2023-01-16
US11642376B2 (en) 2023-05-09
IL268641A (en) 2019-10-31
HUE060548T2 (hu) 2023-03-28
WO2018146297A1 (fr) 2018-08-16
RU2019125600A3 (fr) 2021-11-03
EP4067482A1 (fr) 2022-10-05
ZA201905470B (en) 2024-12-18
KR102666158B1 (ko) 2024-05-16

Similar Documents

Publication Publication Date Title
MA47541A (fr) Procédé permettant de produire des progéniteurs de lymphocytes t
ZA201901870B (en) Process for producing nonwoven
EP3718462A4 (fr) Procédé de détection
EP3302441A4 (fr) Procédés de production du brivaracetam
EP3322659A4 (fr) Procédé et système permettant de former des emballages
SG11201703273SA (en) Process for producing light olefins
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
EP3505540A4 (fr) Procédé de raffinage du sugammadex sodique
EP3438272A4 (fr) Procédé de production de xylo-oligosaccharide
EP3296282A4 (fr) Procédé de production d'hydrohalofluorooléfines
EP3822259A4 (fr) Procédé de synthèse de valsartan
PL3364800T3 (pl) Sposób wytwarzania zasadniczo cylindrycznych artykułów
EP3764172A4 (fr) Procédé de servocommande
EP3513888A4 (fr) Procédé de coulée continue
EP3458948A4 (fr) Procédé de fourniture de notifications
EP3436571C0 (fr) Procédé de culture de lymphocyte b
EP3424894A4 (fr) Procédé de production de butadiène
EP3564245A4 (fr) Dérivé de naphthobischalcogénadiazole et son procédé de production
EP3444253A4 (fr) Procédé de préparation de ad-35
EP3455210A4 (fr) Procédé de préparation de boscalide
SG11201703275TA (en) A process for producing light olefins
EP3343216A4 (fr) Procédé d'analyse pour mycotoxines
GB2524865B (en) Apparatus & process
PL3441765T3 (pl) Sposób wykrywania aktywacji bazofilów
ZA201801650B (en) Process for producing novel 4-benzoazonine derivatives